Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Neuro Oncol. 2023 Sep 5;25(9):1721-1723. doi: 10.1093/neuonc/noad095.

Emre Kocakavuk^{1

2}, Kevin C Johnson¹, Thais S Sabedot³, Hans Christian Reinhardt², Houtan Noushmehr³, Roel G W Verhaak^{1

4}

¹ Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
³ Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan, USA.
⁴ Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.

No abstract available

Keywords: CDKN2A; IDH-mutant; astrocytoma; glioma; hemizygous deletion.

Publication types